.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
This network meta-analysis compared pharmacological and biological treatments for ALS using 109 randomized trials involving 16,353 participants. The primary outcome was change in the ALS Functional Rating Scale–Revised (ALSFRS-R), with respiratory function, mortality and serious adverse events also assessed. Compared with placebo, the combination of cell therapy and neuroprotective agents showed the greatest estimated attenuation of functional decline, with a mean difference of 3.65 points (95% credible interval, 1.27–6.05). Receptor agonists ranked highest for preserving forced vital capacity, while alkaloids ranked highest for estimated mortality reduction. However, no intervention demonstrated a statistically significant survival benefit compared with placebo. The authors highlighted substantial heterogeneity across studies, particularly for some drug classes, and cautioned that treatment rankings should not be interpreted as definitive head-to-head evidence. The analysis suggests that combined biological and neuroprotective strategies warrant further investigation, while comprehensive supportive care remains essential.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This network meta-analysis compared pharmacological and biological treatments for ALS using 109 randomized trials involving 16,353 participants. The primary outcome was change in the ALS Functional Rating Scale–Revised (ALSFRS-R), with respiratory function, mortality and serious adverse events also assessed. Compared with placebo, the combination of cell therapy and neuroprotective agents showed the greatest estimated attenuation of functional decline, with a mean difference of 3.65 points (95% credible interval, 1.27–6.05). Receptor agonists ranked highest for preserving forced vital capacity, while alkaloids ranked highest for estimated mortality reduction. However, no intervention demonstrated a statistically significant survival benefit compared with placebo. The authors highlighted substantial heterogeneity across studies, particularly for some drug classes, and cautioned that treatment rankings should not be interpreted as definitive head-to-head evidence. The analysis suggests that combined biological and neuroprotective strategies warrant further investigation, while comprehensive supportive care remains essential.
Today
A retrospective study of 6,113 adults shows that combining GLP-1 receptor agonists with digital health apps nearly doubles the odds of achieving significant weight loss. Frequent progress logging serves as a primary behavioral driver of long-term metabolic success.
Today
Sexual dysfunction affects a high proportion of reproductive-age females with multiple sclerosis. This comprehensive review highlights multi-tier etiologies, proactive clinical screening tools, preconception counseling considerations, and integrated therapeutic options across multidisciplinary care pathways.
Today
Researchers have engineered an innovative CRISPR-Cas12a fluorescent diagnostic kit for clinical sST2 detection. By combining nanotechnology with enzymatic trans-cleavage, this platform enables rapid, ultrasensitive heart failure diagnosis and risk stratification, outperforming conventional laboratory ELISA methods.
Today
Non-union fractures occur in 2-5% of cases, causing significant disability and cost. Conservative modalities such as LIPUS, PEMF, and focused ESWT offer non-surgical healing options for defects up to 5-10 mm when adequate mechanical stability exists without infection.
Today
India is poised to transform chronic disease management through wearable health technology. Discover how continuous remote monitoring and predictive algorithms empower clinicians to detect early cardiovascular signals, personalize metabolic interventions, and deliver equitable preventive care across populations.
Yesterday
